FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Nanavaty Maulik 		2. Issuer Name and Ticker or Trading Symbol

BOSTON SCIENTIFIC CORP [ BSX ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
SVP & Pres, Neuromodulation
(Last)          (First)          (Middle)

300 BOSTON SCIENTIFIC WAY 		3. Date of Earliest Transaction (MM/DD/YYYY)

8/30/2017
(Street)

MARLBOROUGH, MA 01752-1234
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   8/30/2017     M    10000.0000   A $12.5200   218233.0000   (1) D    
Common Stock   8/30/2017     M    10000.0000   A $7.4100   228233.0000   (1) D    
Common Stock   8/30/2017     M    7031.0000   A $6.2800   235264.0000   (1) D    
Common Stock   8/30/2017     S    27031.0000   D $27.0831   (2) 208233.0000   (1) D    
Common Stock   8/31/2017     M    20000.0000   A $7.4100   228233.0000   (1) D    
Common Stock   8/31/2017     M    10000.0000   A $7.3900   238233.0000   (1) D    
Common Stock   8/31/2017     S    30000.0000   D $27.4513   (3) 208233.0000   (1) D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)   $12.5200   8/30/2017     M         10000.0000      (4) 2/12/2018   Common Stock   10000.0000   $0.0000   15568.0000   D    
Stock Option (Right to Buy)   $7.4100   8/30/2017     M         10000.0000      (5) 2/16/2020   Common Stock   10000.0000   $0.0000   38231.0000   D    
Stock Option (Right to Buy)   $6.2800   8/30/2017     M         7031.0000      (6) 2/27/2022   Common Stock   7031.0000   $0.0000   0.0000   D    
Stock Option (Right to Buy)   $7.4100   8/31/2017     M         20000.0000      (5) 2/16/2020   Common Stock   20000.0000   $0.0000   18231.0000   D    
Stock Option (Right to Buy)   $7.3900   8/31/2017     M         10000.0000      (7) 2/28/2023   Common Stock   10000.0000   $0.0000   34035.0000   D    

Explanation of Responses:
(1)  Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.
(2)  Represents the weighted average sale price. These shares were sold in multiple transactions at $27.08 and $27.09. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
(3)  Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $27.45 to $27.465, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
(4)  Grant to the reporting person of an option to purchase 25,568 shares of common stock vesting in four annual increments beginning on February 12, 2009, the first anniversary of the grant.
(5)  Grant to the reporting person of an option to purchase 48,231 shares of common stock vesting in four annual increments beginning on February 16, 2011, the first anniversary of the grant.
(6)  Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant.
(7)  Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Nanavaty Maulik
300 BOSTON SCIENTIFIC WAY
MARLBOROUGH, MA 01752-1234

SVP & Pres, Neuromodulation

Signatures
/s/ Vance R. Brown, Attorney-in-fact 9/1/2017
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Boston Scientific (NYSE:BSX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Boston Scientific Charts.
Boston Scientific (NYSE:BSX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Boston Scientific Charts.